Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Magazines
Fall Home Improvements
Women
Home & Realty
Outdoor Guide
Premier Home Style Tour 2024
Spring Home & Garden Show
Spring on the Road
Spring Wellness
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
Parcel Pickup
2024 Readersâ Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Cyclacel Pharmaceuti
(NQ:
CYCC
)
0.3450
-0.0090 (-2.54%)
Streaming Delayed Price
Updated: 4:00 PM EST, Nov 27, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Cyclacel Pharmaceuti
< Previous
1
2
3
4
5
6
Next >
Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2023 Financial Results
March 13, 2024
From
Cyclacel
Via
GlobeNewswire
Cyclacel Pharmaceuticals Announces Preclinical Proof-of-Concept Data for Fadraciclib to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2024
March 07, 2024
Data support ongoing development program of novel CDK2/9 inhibitor fadraciclib in patients with solid tumors and lymphoma
From
Cyclacel
Via
GlobeNewswire
Cyclacel Pharmaceuticals Announces Receipt of $2.9 Million R&D Tax Credit
March 06, 2024
From
Cyclacel
Via
GlobeNewswire
Cyclacel Pharmaceuticals to Participate in 2024 BIO CEO & Investor Conference
February 20, 2024
From
Cyclacel
Via
GlobeNewswire
Cyclacel Pharmaceuticals Announces the Appointment of Brian Schwartz, M.D. as Chief Medical Officer
January 30, 2024
From
Cyclacel
Via
GlobeNewswire
12 Health Care Stocks Moving In Monday's Intraday Session
January 15, 2024
Via
Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
January 12, 2024
Via
Benzinga
RKLB Stock Alert: The $500 Million Reason Rocket Lab Is Moving Today
January 09, 2024
Rocket Lab stock is on the move Tuesday as investors in RKLB react to a new $515 million contract with Space Development Agency.
Via
InvestorPlace
Unity Layoffs 2024: What to Know About the Latest U Job Cuts
January 09, 2024
Unity layoffs are on the way as the video game software company reveals plans to cut 1,800 jobs to focus on its core business.
Via
InvestorPlace
Topics
Workforce
Exposures
Layoff
Why Is Cyclacel Pharmaceuticals (CYCC) Stock Down 9% Today?
January 09, 2024
Cyclacel Pharmaceuticals stock is slipping on Tuesday after shares of CYCC rallied on Monday alongside it regaining Nasdaq compliance.
Via
InvestorPlace
Why Juniper Networks Shares Are Trading Higher By Over 23%; Here Are 20 Stocks Moving Premarket
January 09, 2024
Shares of Juniper Networks, Inc. (NYSE: JNPR) rose sharply in pre-market trading on Tuesday.
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
January 09, 2024
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
January 09, 2024
Pre-market stock movers are worth checking out on Tuesday to catch up on all of the hottest stock market news for this morning!
Via
InvestorPlace
Why RxSight Shares Are Trading Higher By 20%? Here Are Other Stocks Moving In Monday's Mid-Day Session
January 08, 2024
Shares of RxSight, Inc. (NASDAQ: RXST) rose sharply during Monday’s session after the company issued preliminary FY23 and FY24 revenue guidance above estimates. Also, Needham maintained a Buy rating on...
Via
Benzinga
Cyclacel Pharmaceuticals Regains Compliance With Nasdaq Minimum Bid Price Requirement
January 08, 2024
From
Cyclacel
Via
GlobeNewswire
Why LumiraDx Shares Are Trading Lower By Over 30%; Here Are 20 Stocks Moving Premarket
January 08, 2024
Shares of LumiraDx Limited (NASDAQ: LMDX) shares fell sharply in pre-market trading. LumiraDx announced its securities will be suspended from trading on Nasdaq at the open of business on Jan. 9th....
Via
Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
January 08, 2024
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
January 08, 2024
It's time to start the week with a breakdown of the biggest pre-market stock movers worth keeping an eye on for Monday morning!
Via
InvestorPlace
Why Applied Therapeutics Shares Are Trading Lower By Over 35%? Here Are Other Stocks Moving In Friday's Mid-Day Session
January 05, 2024
Shares of Applied Therapeutics, Inc.
Via
Benzinga
Cyclacel Pharmaceuticals to Present at Biotech Showcase 2024
January 02, 2024
From
Cyclacel
Via
GlobeNewswire
12 Health Care Stocks Moving In Monday's Intraday Session
December 25, 2023
Via
Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
December 25, 2023
Via
Benzinga
Why AAR Shares Are Trading Lower By 7%? Here Are Other Stocks Moving In Friday's Mid-Day Session
December 22, 2023
Shares of AAR Corp. (NYSE: AIR) fell during Friday’s session after the company reported mixed second-quarter financial results.
Via
Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
December 22, 2023
Via
Benzinga
Dow Rises 50 Points; Fed's Preferred Inflation Gauge Cools In November
December 22, 2023
U.S. stocks traded higher this morning, with the Dow Jones index gaining more than 50 points on Friday. Following the market opening Friday, the Dow traded up 0.14% to 37,458.12 while the NASDAQ rose...
Via
Benzinga
Topics
Economy
Stocks
Exposures
Interest Rates
US Equities
Why Cyclacel Pharmaceuticals (CYCC) Shares Are Getting Obliterated
December 22, 2023
Cyclacel Pharmaceuticals Inc (NASDAQ: CYCC) shares are trading lower by 26.9% to $2.63 Friday morning after the company announced it finalized an agreement to sell 388,200 shares of its common stock at...
Via
Benzinga
Cyclacel Pharmaceuticals Announces Registered Direct and Private Placement Offering Priced At-The-Market Under Nasdaq Rules
December 22, 2023
From
Cyclacel
Via
GlobeNewswire
CYCC Stock Earnings: Cyclacel Pharmaceuticals Beats EPS for Q1 2023
December 20, 2023
CYCC stock results show that Cyclacel Pharmaceuticals beat analyst estimates for earnings per share the first quarter of 2023.
Via
InvestorPlace
CYCC Stock Earnings: Cyclacel Pharmaceuticals Beats EPS for Q2 2023
December 20, 2023
CYCC stock results show that Cyclacel Pharmaceuticals beat analyst estimates for earnings per share the second quarter of 2023.
Via
InvestorPlace
CYCC Stock Earnings: Cyclacel Pharmaceuticals Misses EPS for Q3 2023
December 20, 2023
CYCC stock results show that Cyclacel Pharmaceuticals missed analyst estimates for earnings per share the third quarter of 2023.
Via
InvestorPlace
< Previous
1
2
3
4
5
6
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.